Raisa Alekseevna Chilova

Raisa Alekseevna Chilova

Auto-generated profile, based on publicly available information

Raisa Alekseevna Chilova

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Russian Journal of Woman and Child Health
Verified
Journal Article
Open access
RCR.A. Chilova
R.A. Chilova
GPG.F. Proklova
G.F. Proklova
NGN.V. Goncharenko
N.V. Goncharenko
Диагностика и лечение бактериального вагиноза. Правильный выбор препаратов, обладающих наибольшей эффективностью воздействия на большинство микроорганизмов, вызывающих бактериальный вагиноз. Клиндамицин

1 January 2021 in Voprosy Ginekologii, Akušerstva i Perinatologii
Verified
Journal Article
Closed access
GPG.F. Proklova
G.F. Proklova
ESE.A. Sokova
E.A. Sokova
RKR.E. Kazakov
R.E. Kazakov
RCR.A. Chilova
R.A. Chilova
EZE.V. Zhukova
E.V. Zhukova
MPMoscow Scientific Centre For Expert Evaluation Of Medicinal Products
Moscow Scientific Centre For Expert Evaluation Of Medicinal Products
Tocolytic therapy with the use of β2-agonist hexoprenaline is used to prolong pregnancy. Polymorphisms of the ADRB2 gene can affect the efficacy and safety of this drug, including missense mutations associated with the Gly16Arg and Gln27Glu substitutions. Objective. To study the role of the ADRB2 gene polymorphism in preterm birth, as well as the efficiency and safety of tocolytic therapy with hexoprenaline. Patients and methods. 120 pregnant women were examined. The main group included 60 pregnant women who were at risk of preterm birth and to whom intravenous tocolytic therapy with hexoprenaline was performed. In the control group (n = 60), there was a woman whose pregnancy was not accompanied by the threat of preterm birth, and delivery itself was emergency and spontaneous. The identification of the Gly16Arg and Gln27Glu polymorphisms of the ADRB2 gene was carried out by the PCR-RFLP method. Results. In pregnant women with the threat of premature labor, the 16Arg allele (p = 0.028) was less common, and the 16Gly/Gly genotype (p = 0.027) of the ADRB2 gene was reliably more common. Adverse reactions to hexoprenaline occured in 53% of pregnant women: in 47%, it was tachycardia, in 6% – headache. Their incidence was not associated with the ADRB2 gene polymorphism. Conclusion. The effectiveness of hexoprenaline is lower in the carriers of genotypes indicating high or low expression of β2-adrenoreceptors. Key words: hexoprenaline, genotyping, single-nucleotide polymorphisms, preterm birth, tocolytic therapy, ADRB2

7 January 2022 in Pharmacogenetics and Pharmacogenomics
Verified
Journal Article
Open access
PDF file
RKR. E. Kazakov
R. E. Kazakov
RCR. A. Chilova
R. A. Chilova
KAK. O. Akopov
K. O. Akopov
ESE. A. Sokova
E. A. Sokova
This article discusses issues related to the role of polymorphism of the ADRB2 gene encoding β2-adrenergic receptor in preterm labor and tocolysis. Information is provided on scientific studies related to the search for associations of the carriage of alleles and genotypes of ADRB2 with the preterm labor, as well as with the pharmacological response to tocolytic therapy using β2-adrenergic agonists. The history of the discovery of the relationship of ADRB2 gene polymorphisms with preterm labor is presented in chronological order. As scientific facts emerge, researchers are faced with the question: how can ADRB2 gene polymorphisms affect physiological processes? That is, whether they affect by changing the primary structure of the receptor or by changing the level of expression. Depending on the answer to this question, pharmacogenetics are faced with a further task: what to study - individual polymorphisms or haplotypes?

1 January 2025 in Voprosy Ginekologii, Akušerstva i Perinatologii
Verified
Journal Article
Closed access
ADA.I. Davydov
A.I. Davydov
VRV.E. Radzinsky
V.E. Radzinsky
AIA.I. Ishchenko
A.I. Ishchenko
MKM.B. Khamoshina
M.B. Khamoshina
RCR.A. Chilova
R.A. Chilova
MDM.F. Dorfman
M.F. Dorfman
For several decades, the problem of ovarian endometriosis has been the focus of attention of scientists all over the globe. However, it remains a relevant issue and is the subject of numerous discussions and debates. One of the key topics in this problem are still the management tactics and strategies for patients with ovarian endometriomas. Generally, these are young women, and their treatment should be aimed at preserving their reproductive potential, which is initially impaired by ovarian endometriosis. Oncological caution and the toxicity of ovarian endometriomas together indicate the need for surgical treatment. From a critical perspective based on personal experience and data from recent international publications, all currently available organ-preserving surgical methods used in patients with ovarian endometriomas are reviewed: cystectomy, ablation, and sclerotherapy. The aggressiveness of cystectomy in relation to ovarian reserve is demonstrated, and the limitations of ablation and ethanol sclerotherapy are emphasized. Special attention is paid to the prevention of postoperative recurrence of ovarian endometriomas, in which hormone therapy plays an important role. In this context, the advantages of combined oral contraceptives containing dienogest are justified. Key words: ovarian endometriosis, endometriomas, cystectomy, ablation, sclerotherapy, recurrence prevention, dienogest

30 December 2021 in Лечащий врач
Verified
Journal Article
Closed access
KBK.R. Bahtiyarov
K.R. Bahtiyarov
RCR.A. Chilova
R.A. Chilova
SSS.SH. Sardarova
S.SH. Sardarova
The article is devoted to the study of modern methods of diagnosis and treatment of benign diseases of the vulva and vagina in postmenopausal women. The analysis of the etiology, clinical picture, methods of diagnosis and treatment of vulvovaginal atrophy, as the most common benign disease of the vulva and vagina in postmenopausal women, has been carried out. It has been established that the main factor leading to vulvovaginal atrophy in postmenopausal women is climacteric hormonal imbalance with a gradually increasing estrogen deficiency. Postmenopausal women note such signs of vulvovaginal atrophy as vaginal dryness, burning and itching, dyspareunia, hypersensitivity to infectious diseases of the pelvic organs, which significantly aggravates the state of health, a negative effect on the general and sexual quality of life. Diagnosis of vulvovaginal atrophy is based on examination data, laboratory and instrumental studies. The main therapeutic goal in the treatment of vulvovaginal atrophy is to relieve symptoms and restore the vaginal environment to a healthy premenopausal state. The «gold standard» for the treatment of vulvovaginal atrophy is local and systemic estrogen therapy. HRT drugs contribute to an increase in proliferative processes, an improvement in blood supply, a rapid normalization of the vaginal microflora and can be prescribed for therapeutic and prophylactic purposes. For the treatment of vulvovaginal atrophy in women for whom estrogen preparations are contraindicated, selective estrogen receptor modulators are used. The drugs in this group, ospemifen and lasofoxifene, help to alleviate the symptoms of vaginal atrophy and dyspareunia, improve vaginal epithelium and vaginal pH. Also, with mild symptoms, an improvement in the condition occurs with the use of non-hormonal vaginal lubricants. In addition, there are experimental options for vulvovaginal rejuvenation in women with symptoms that do not fit or tolerate local or systemic estrogen therapy: platelet-rich plasma injections, hyaluronic acid or fat implants, fractional carbon dioxide laser, diode laser and monopolar radiofrequency devices, vaginoplasty.

1 January 2021 in Voprosy Ginekologii, Akušerstva i Perinatologii
Verified
Journal Article
Closed access
ADA.I. Davydov
A.I. Davydov
DID.V. Isakov
D.V. Isakov
RCR.а. Chilova
R.а. Chilova
VLV.A. Lebedev
V.A. Lebedev
MSM.N. Shakhlamova
M.N. Shakhlamova
A clinical and immunological analysis of the use of antiviral agent Inosine Pranobex (IP) as postoperative drug therapy in patients with cervical intraepithelial neoplasia (CIN) associated with human papillomavirus (HPV) is performed. It is known that IP has a high anti-relapse activity adapted to the mechanisms of HPV elimination (through the sequence of oncoproteins E5, E6 and E7, a decrease in the synthesis of interferons (IFNs) occurs and resistance of HPV-infected cells to IFN is formed). In this work, a number of statements justifying the priority of IP in the treatment of patients with CIN associated with HPV is covered, namely that IP induces trained immunity, differentiation of the Th1 subset of CD4+ T cells and proliferation of CD8+ T cells. Conclusion. Inosine Pranobex should be considered as the medication of choice for postoperative monotherapy in patients with HPV-associated CIN. Inosine Pranobex is characterized by mechanisms of action in both virus-infected cells and through the activation of innate and adaptive immune cells. Key words: CIN, human papillomavirus, inosine pranobex, clinical and immunological aspects, trained immunity